摘要
Abstract
Objective To observe the therapeutic effect and safety of volumetric modulated arc therapy(VMAT)combined with sintilimab(SIN)in treating advanced esophageal squamous cell carcinoma(ESCC).Methods From July 2022 to July 2024,82 patients with advanced ESCC admitted to the PLA 922 Hospital were randomly assigned into the control group(41 cases,VMAT)and test group(41 cases,VMAT combined with SIN)via a random number table.The therapeutic effect,tumor markers,cellular immune function,and safety were compared.Results Patients in the test group had significantly higher effective rate and incidence of blood toxicity(grades 3-4)than those of the control group(P＜0.05).After treatment,carcinoembryonic antigen(CEA)and squamous cell carcinoma antigen(SCC)in both groups were significantly lower than those before treatment,which were significantly lower in the test group than the control group(P＜0.05).After treatment,CD3+and CD4+in both groups were significantly higher than those before treatment,which were significantly higher in the test group than the control group(P＜0.05).Conclusion VMAT combined with SIN has an obvious therapeutic effect on advanced ESCC.It can reduce CEA and SCC,and improve cellular immune function,although a concern should be made on the occurrence of blood toxicity.关键词
容积旋转调强放疗/信迪利单抗/晚期/食管鳞癌/疗效/安全性Key words
Volumetric modulated arc therapy/Sintilimab/Advanced/Esophageal squamous cell carcinoma/Therapeutic effect/Safety分类
临床医学
